Elsevier

Lung Cancer

Volume 66, Issue 3, December 2009, Pages 275-281
Lung Cancer

Review
Cancer stem cell: Implications in cancer biology and therapy with special reference to lung cancer

https://doi.org/10.1016/j.lungcan.2009.07.019Get rights and content

Abstract

The cancer stem cell (CSC) theory is currently central to the field of cancer research, because it is not only a matter of academic interest but also crucial in cancer therapy. CSCs share a variety of biological properties with normal somatic stem cells in terms of self-renewal, the propagation of differentiated progeny, the expression of specific cell markers and stem cell genes, and the utilization of common signaling pathways and the stem cell niche. However, CSCs differ from normal stem cells in their tumorigenic activity. Thus, CSCs are also termed cancer initiating cells. In this paper, we briefly review hitherto described study results and refer to some excellent review articles to understand the basic properties of CSCs. In addition, we focus upon CSCs of lung cancers, since lung cancer is still increasing in incidence worldwide and remains the leading cause of cancer deaths. Understanding the properties of, and exploring cell markers and signaling pathways specific to, CSCs of lung cancers, will lead to progress in therapy, intervention, and improvement of the prognosis of patients with lung cancer. In the near future, the evaluation of CSCs may be a routine part of practical diagnostic pathology.

Introduction

Current investigations in the field of cancer research intensively focus upon the “cancer stem cell (CSC)”. The CSC theory appears to be well established and now widely accepted [1], [2], [3], [4], [5], [6], [7], though some controversies still remain [8], [9], [10], [11], [12], [13], [14]. The CSC, similar to a normal stem cell, is capable of self-renewal and the production of differentiated progeny. In addition, the human CSC has a capacity to form secondary/tertiary tumors upon serial xenotransplantation into immunocompromised rodents, the features of which mimic the original tumors. The demonstration of these three capacities is the golden standard to identifying human CSCs, and such features of CSCs reflect the activity of cancer initiation, recurrence, therapy-resistance, and metastasis, all of which are critical in cancer therapy. The term CSC is frequently used to mean “cancer initiating cell (CIC)”. In this article, we briefly discuss the general features of CSCs. We also focus upon the characteristics of CSCs in lung cancers, since lung cancer is the leading cause of cancer deaths worldwide and one of the most intractable cancers.

Section snippets

Origin of cancer stem cells

In earlier years, it was unclear whether CSCs originate only from normal (somatic) stem cells or also from non-stem progenitors or differentiating cells. Recent evidence strongly favors a progenitor cell origin for many types of leukemic stem cells in addition to the stem cell origin [2]. In solid tumors too, it is most likely that not only somatic stem cells but also differentiating progenitor cells are capable of becoming CSCs [5]. Rapp et al. [3] proposed a model of oncogene-induced

General remarks

The compartment of CSCs comprises a very small fraction of the entire cancer cell population; thus, it is necessary to utilize specific markers, such as CD34 in several kinds of leukemia and CD44 in breast cancers, colorectal cancers, pancreas cancers, prostate cancers, head/neck cancers and some bone sarcomas, to detect and isolate CSCs from among the innumerable cancer cells and stromal cells occupying the entire tumor tissue [5], [13], [15], [16]. Representative cell surface markers for

Stem cells in healthy and injured lung

Although the airway stem cell in a strict sense has not been identified yet, several lines of evidence support the existence of regional progenitors cells, such as bronchioloalveolar progenitor cells, basal/mucous secretory bronchial progenitor cells, and neuroendocrine progenitor cells, which maintain the normal homeostasis as well as play roles for repairing injuries [63], [64], [65]. These progenitor cells expand their populations in response to various insults including toxic substances,

Conclusion and perspective

The CSC theory is tremendously attractive to both researchers and physicians, because the CSC is central to cancer cell biology and cancer therapy. The discovery of specific markers of CSCs in the respective types of cancers is particularly important. Furthermore, it is necessary to clarify the function of these molecules, as the disruption of the signaling pathways and gene transcriptions that control the activity of CSCs is the final goal of CSC-targeting therapy. We would like to emphasize

Conflict of interest statement

There is no conflict of interest.

References (87)

  • Y. Yu et al.

    AC133-2, a novel isoform of human AC133 stem cell antigen

    J Biol Chem

    (2002)
  • N. Taïeb et al.

    The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif

    Cancer Lett

    (2009)
  • C. Wu et al.

    Side population cells in human cancers

    Cancer Lett

    (2008)
  • N.A. Sophos et al.

    Aldehyde dehydrogenase gene superfamily: the 2002 update

    Chem Biol Interact

    (2003)
  • R.J. Jones et al.

    Assessment of aldehyde dehydrogenase in viable cells

    Blood

    (1995)
  • C. Ginestier et al.

    ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

    Cell Stem Cell

    (2007)
  • J.B. Sneddon et al.

    Location, location, location: the cancer stem cell niche

    Cell Stem Cell

    (2007)
  • C. Blanpain et al.

    Epithelial stem cells: turning over new leaves

    Cell

    (2007)
  • J.M. Sung et al.

    Characterization of a stem cell population in lung cancer A549 cells

    Biochem Biophys Res Commun

    (2008)
  • D. Ucar et al.

    Aldehyde dehydrogenase activity as a functional marker for lung cancer

    Chem Biol Interact

    (2009)
  • M. Patel et al.

    ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors

    Lung Cancer

    (2008)
  • L.K. Koch et al.

    Stem cell marker expression in small cell lung carcinoma and developing lung tissue

    Hum Pathol

    (2008)
  • X. Liao et al.

    Aberrant activation of hedgehog signaling pathway contributes to endometrial carcinogenesis through beta-catenin

    Mod Pathol

    (2009)
  • M.F. Clarke et al.

    Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells

    Cancer Res

    (2006)
  • N.A. Lobo et al.

    The biology of cancer stem cells

    Annu Rev Cell Dev Biol

    (2007)
  • U.R. Rapp et al.

    Oncogene-induced plasticity and cancer stem cells

    Cell Cycle

    (2008)
  • Y.M. Yang et al.

    Current status and issues in cancer stem cell study

    Cancer Invest

    (2008)
  • X. Li et al.

    Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

    J Natl Cancer Inst

    (2008)
  • L. Li et al.

    Genomic instability en route to and from cancer stem cells

    Cell Cycle

    (2009)
  • R.P. Hill

    Identifying cancer stem cells in solid tumors: case not proven

    Cancer Res

    (2006)
  • P.N. Kelly et al.

    Tumor growth need not be driven by rare cancer stem cells

    Science

    (2007)
  • M.T. Lewis

    Faith, heresy and the cancer stem cell hypothesis

    Future Oncol

    (2008)
  • L. Vezzoni et al.

    Limitations of the cancer stem cell theory

    Cytotechnology

    (2008)
  • J.E. Visvader et al.

    Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

    Nat Rev Cancer

    (2008)
  • K. Rowan

    Are cancer stem cells real? After four decades, debate still simmers

    J Natl Cancer Inst

    (2009)
  • S.M. Ahn et al.

    Stem cell markers: insights from membrane proteomics?

    Proteomics

    (2008)
  • F. Lanza et al.

    Structural and functional features of the CD34 antigen: an update

    J Biol Regul Homeost Agents

    (2001)
  • R. Marhaba et al.

    CD44 and EpCAM: cancer-initiating cell markers

    Curr Mol Med

    (2008)
  • A. Eramo et al.

    Identification and expansion of the tumorigenic lung cancer stem cell population

    Cell Death Differ

    (2008)
  • C. Wuchter et al.

    Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping

    Haematologica

    (2001)
  • N. Uchida et al.

    Direct isolation of human central nervous system stem cells

    Proc Natl Acad Sci USA

    (2000)
  • G.D. Richardson et al.

    CD133, a novel marker for human prostatic epithelial stem cells

    Cell Sci

    (2004)
  • C. Piechaczek

    CD133

    J Biol Regul Homeost Agents

    (2001)
  • Cited by (85)

    • miR-150-5p Inhibits Non-Small-Cell Lung Cancer Metastasis and Recurrence by Targeting HMGA2 and β-Catenin Signaling

      2019, Molecular Therapy Nucleic Acids
      Citation Excerpt :

      Therefore, elucidation of the mechanisms underlying chemoresistance, metastasis, and recurrence is fundamental for the development of new therapeutic strategies in NSCLC. Accumulating evidence shows that cancer stem cells (CSCs) play crucial roles in the development of chemoresistance, metastasis, and recurrence in cancers, including NSCLC.6,7 CSCs are a small subpopulation of tumor cells with stem cell-like properties, such as self-renewal and differentiation, and they are highly resistant to chemotherapy.8

    • Wnt/β-catenin modulates chronic tobacco smoke exposure-induced acquisition of pulmonary cancer stem cell properties and diallyl trisulfide intervention

      2018, Toxicology Letters
      Citation Excerpt :

      In line with previous studies, in the present study, we found that chronic CSE exposure resulted in morphological change from epithelial shaped to spindle-like form, reduced the cell double-time, and promoted the migratory capacity of HBE cell. CSCs have the capacity to initiate tumorigenesis by undergoing self-renewal and differentiation which lead to tumor relapse, therapy resistance, and metastasis (Kitamura et al., 2009; Reya et al., 2001; Wicha et al., 2006). The characteristic of expressing specific markers has been commonly used to identify and isolate CSCs.

    View all citing articles on Scopus
    View full text